SCHEMBL369828

SCHEMBL369828

ClC1CN(c2ncc3nc[nH]c3n2)CCO1

nearest known ligand 0.33

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 6/20 0.33
ALDH1A1 P00352 5/20 0.33
HSD17B10 Q99714 5/20 0.33
CYP3A4 P08684 4/20 0.33
CYP2C9 P11712 3/20 0.33
TSHR P16473 3/20 0.33
USP2 O75604 3/20 0.33
HPGD P15428 2/20 0.33
CYP2C19 P33261 2/20 0.33
MEN1 O00255 1/20 0.33
MAPK1 P28482 1/20 0.33
CASP1 P29466 1/20 0.33
BRCA1 P38398 1/20 0.33
KMT2A Q03164 1/20 0.33
CLK4 Q9HAZ1 2/20 0.32
CHEK1 O14757 1/20 0.31
KDM4E B2RXH2 1/20 0.31
CYP2D6 P10635 1/20 0.31
IGF1R P08069 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL336705 0.79 KDM4E (0.49) CYP1A2ALDH1A1HSD17B10CYP3A4CYP2C9
SCHEMBL30677292 0.79 KDM4E (0.49) CYP1A2ALDH1A1HSD17B10CYP3A4CYP2C9
SCHEMBL11611665 0.74 IP6K1 (0.44) ALDH1A1TSHRUSP2MAPK1CASP1
SCHEMBL15322620 0.73 IP6K1 (0.43) ALDH1A1TSHRUSP2MAPK1
SCHEMBL5720613 0.71 CHEK1 (0.47) MAPK1CHEK1
SCHEMBL2725269 0.70 CYP1A2 (0.34) CYP1A2ALDH1A1HSD17B10CYP3A4CYP2C9
SCHEMBL4244418 0.68 USP2 (0.32) CYP1A2ALDH1A1HSD17B10CYP3A4CYP2C9
SCHEMBL2726529 0.67 PDE10A (0.37) CYP1A2ALDH1A1HSD17B10CYP3A4CYP2C9
SCHEMBL18894258 0.66 MTOR (0.38)
SCHEMBL9854783 0.63 MAPK8 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593455-B1 PURINE COMPOUNDS SELECTIVE FOR I3 P110 DELTA, AND METHODS OF USE HOFFMANN LA ROCHE (CH) 2015-03-18 EP disclosed
EP-2593455-A1 PURINE COMPOUNDS SELECTIVE FOR I3 P110 DELTA, AND METHODS OF USE F.HOFFMANN-LA ROCHE AG (CH) 2013-05-22 EP disclosed
US-8293736-B2 Purine compounds selective for PI3K P110 delta, and methods of use F. HOFFMANN LA ROCHE AG (CH) 2012-10-23 US disclosed
US-20120015931-A1 PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-01-19 US disclosed
WO-2012007493-A1 PURINE COMPOUNDS SELECTIVE FOR ΡI3Κ P110 DELTA, AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015931-A1 PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE PIK3CA, PIK3CD, PIK3CG CYP1A2 1169/4885ALDH1A1 4331/4885HSD17B10 3498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.